Forxiga will be accepted to be used for the dual therapy with insulin while Suglat is going to be newly registered
The insurance benefit standard of diabetes drugs has been expanded. Followed by DPP-4 inhibitors, the dual therapy of a SGLT-2 inhibitor, ‘Forxiga(dapagliflozin),’ is also expected to be applied in the standard.
The Ministry of Health and Welfare has administratively notified an amendment for th...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
